Try GOLD - Free

India Needs Proper Biosupplier Ecosystem

Bio Spectrum

|

September 2017

With economic growth and addition of biotechnology to its portfolio, India is rapidly becoming a global player in the life sciences and healthcare space. Educating and achieving scientific excellence demands a really high level of R&D. Now that the government is investing more resources in research and medical facilities and infrastructure, from educational institutes to hospitals, use of lab equipment, reagents or medical devices are growing rapidly. This will drive the growth of biosupplier market in the country.

India Needs Proper Biosupplier Ecosystem

India’s life sciences and healthcare industry has changed dramatically in the last decade, moving from import dependency to self-sufficiency, and this has created demand for innovative new technologies. Fueling this growth has been increasing demand from biosuppliers who are challenged to provide innovative and productive solutions that not only support India, but also enable them to compete globally.

Other notable trends in the past few years have been an intensive focus on R&D within pharmaceutical, biotech and healthcare as well as demand from the government sector (mainly R&D institutes). “This has led to new investments in high-end analytical instruments and consumables to support everything from food safety and drug discovery to precision medicine,” said Amit Chopra, Managing Director – India and Middle East, Thermo Fisher Scientific while commenting on trends in biosuppliers market with respect to life sciences and healthcare industry in India.

Biosuppliers are witnessing unprecedented growth opportunities in India due to high growth in the Biopharma and healthcare market. Pharmaceuticals, life sciences and healthcare companies are experiencing a wave of competing challenges currently.

Sharing her views on trends in biosuppliers Dr Deepanwita Chattopadhyay, Chairman & CEO, IKP Knowledge Park said “We have started producing the reagents in the country but a large amount is still being imported. I am seeing people getting into the reagents and suppliers business. It’s also about acceptance. The market depends also on buyers and not just sellers. If academic institutions and companies buy the Indian product and if they can establish the confidence then only their share in the market will increase. I think this process has already been started and slowly picking up.”

MORE STORIES FROM Bio Spectrum

Bio Spectrum

Bio Spectrum

WHO certifies Suriname malaria-free

Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation

Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.

time to read

1 min

August 2025

Bio Spectrum

Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab

Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.

time to read

1 min

August 2025

Bio Spectrum

Illumina buys SomaLogic for $425 M to accelerate proteomics business

Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26

Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.

time to read

1 min

August 2025

Bio Spectrum

WHO highlights risks associated with use of semaglutide medicines

The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin

Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru

AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Novo Nordisk launches injectable Semaglutide for weight management in India

Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?

India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.

time to read

12 mins

August 2025

Translate

Share

-
+

Change font size